

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-268

Correspondence

Electronic Mail Message

Date: 6/25/01 1:32:10 PM
From: Athey, Judy (Judy.Athey@unimed.solvay.com)
To: 'birdsongs@cder.fda.gov' (birdsongs@A1)
Cc: Gallo, Frank (Frank.Gallo@solvay.com)
Cc: Outwater, Robert (Robert.Outwater@unimed.solvay.com)
Cc: Vlasak, Kelly (Kelly.Vlasak@unimed.solvay.com)
Cc: [(]
Subject: NDA 21-268

Dear Ms. Birdsong:

As requested by telephone on 18 June 2001 and clarified on 25 June 2001, following is a statement regarding published literature in NDA 21-268.

Teveten[®] HCT (eprosartan/hydrochlorothiazide) NDA 21-268 was submitted 30 August 2000 and included eight adequate and well-controlled clinical studies.

The NDA also included published literature references related to the data discussed in the clinical section of the NDA. These published literature references alone are not sufficient to support approval of Teveten[®] HCT.

Judy Athey
Manager, Regulatory Affairs
June 2001

Judy Athey
Manager, Regulatory Affairs
Unimed Pharmaceuticals, Inc.
Four Parkway North, Suite 200
Deerfield, Illinois 60015-2544
847-282-5423 telephone 847-282-5740 fax
judy.athey@unimed.solvay.com
<http://www.unimed.com>


UNIMED

PHARMACEUTICALS, INC.

A Solvay Pharmaceuticals, Inc. Company

 Unimed Pharmaceuticals, Inc.
 Four Parkway North, Suite 200
 Deerfield, IL 60015
 847-282-5400
 847-282-5740 FAX

FAX . . .

Date: 09 July 2001	No. of Pages: 1
To: Sandy Birdsong, Project Manager Division of Cardio-Renal Drug Products, HFD-110	From: Judy Athey Manager, Regulatory Affairs
Phone: 301-594-5334	Phone: 847-282-5423
Fax: 301-594-5495	Fax: 847-282-5740

Dear Ms. Birdsong:

This communication is to provide the Division with a list of participants for a teleconference between Drs. Lipicky, Stockbridge and Unimed Pharmaceuticals, Inc. regarding the proposed labeling for NDA 21-268, Teveten® (esprosartan mesylate/hydrochlorothiazide).

The teleconference is scheduled for 3:30-5:00 p.m. (Eastern Standard Time). The dial in number for the teleconference is 800-621-1914; participant code is 143267.

Following are participants for Unimed:

Judy Athey, Unimed Pharmaceuticals, Inc.

 [
 Henk Plum, Ph.D., Solvay BV
 Claus Steinborn, M.D., Solvay BV
 Frans Coenen, Ph.D., Solvay BV
]

Please telephone me if you have questions.

 Signature Judy Athey

 Date 09 July 2001
NOTICE OF CONFIDENTIALITY

The information contained in this facsimile transmission is confidential information and may be legally privileged information, protected work-product or a trade secret under applicable law. The information is intended solely for the use of the individual or entity named above. If you are not the named recipient, or an employee or agent responsible for delivering this facsimile transmission to the named recipient, you are hereby notified that you have received this transmission in error and that any review, disclosure, copying, dissemination, usage or taking of any action in reliance on any information contained in this facsimile transmission is forbidden by the sender and may be illegal. If you have received this facsimile transmission in error, please call us collect at the number printed above to arrange return of this complete transmission to us at our expense. Thank you.

If You Experience Problems with this Transmission - Please Call the Number Listed Above



Four Parkway North
Deerfield, IL 60015-2544
847-282-5400
Fax 847-374-8480

05 July 2001



Raymond J. Lipicky, M.D., Director
Division of Cardio-Renal Drug Products, HFD-110
Food and Drug Administration
Woodmont Office Complex 2, Room 5039
1451 Rockville Pike
Rockville, MD 20852

**RE: TEVETEN® HCT (eprosartan mesylate/hydrochlorothiazide) Tablets
NDA 21-268
General Correspondence: Notification of Intent to File Amendment**

Dear Dr. Lipicky:

Reference is made to Unimed Pharmaceuticals, Inc., pending NDA 21-268 for TEVETEN® HCT (eprosartan mesylate/hydrochlorothiazide) 600/12.5 and 600/25 mg Tablets, submitted 30 August 2000 and to the Agency's approvable letter of 27 June 2001. Unimed intends to file an amendment to this application as soon as the information is available to address the Agency's comments.

Should you have any questions about the information contained in this submission, please contact me at 847-282-5423.

Sincerely,


Judy Athey
Manager, Regulatory Affairs

Enclosures

cc: Sandy Birdsong, Project Manager, FDA (cover letter only)



Four Parkway North
Deerfield, IL 60015-2544
847-282-5400
Fax 847-374-8480



May 24, 2001

Raymond J. Lipicky, M.D., Director
Division of Cardio-Renal Drug Products, HFD-110
Food and Drug Administration
Woodmont Office Complex 2, Room 5039
1451 Rockville Pike
Rockville, MD 20852

**Re: Teveten®HCT
(eprosartan mesylate/hydrochlorothiazide) Tablets
IND [redacted] Serial Number 435
General Correspondence: Final Study Report**

Dear Dr. Lipicky:

Reference is made to Unimed Pharmaceuticals, Inc. New Drug Application 21-268 dated 30 August 2000 for Teveten® HCT (eprosartan mesylate/hydrochlorothiazide) Tablets and to the 25 April 2001 submission of a Final Bioavailability Study Report for Study CR 1711006.01: *A Randomized, Single-Dose, Two-Period, Cross-Over Study to Compare the Bioavailability of One Combination Tablet of Eprosartan 600 mg/Hydrochlorothiazide 25 mg Relative to the Coadministration of One 600 mg Eprosartan Tablet and One 25 mg Hydrochlorothiazide Tablet in Healthy Male and Female Volunteers.*

Draft summary reports were submitted to IND [redacted] on 15 May 2001 in response to a telephone request on 07 May 2001 by Drs. Patrick Marroum and Angelica Dorantes, Biopharmaceutics Reviewers for NDA 21-268, Teveten® HCT.

The purpose of this submission is to provide a Final Study Report for *The Determination of Eprosartan in*

[redacted] which contains the method validation for the analysis of eprosartan; and *The Determination of Hydrochlorothiazide in*

[redacted] which contains the method validation for the analysis of hydrochlorothiazide.

IND Serial Number 435
24 May 2001
Page 2 of 2

Should you have any questions or need additional information, please contact me at (847) 282-5423.

Sincerely,



Judy Athey
Manager, Regulatory Affairs

Attachment

cc: Sandy Birdsong, Project Manager, FDA (cover letter only)

423-989-8055 DIVISION OF CARDIO-RENAL DRUG PRODUCTS
FOOD AND DRUG ADMINISTRATION



US Mail address:
FDA/CDER/HFD-110
5600 Fishers Lane
Rockville, MD 20857

Woodmont II
1451 Rockville Pike
Rockville, MD 20852

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to: CDER, DCRDP (HFD-110); 5600 Fishers Lane; Rockville, MD 20857

Transmitted to FAX Number: 847-282-5740

Attention: Mr. Michael O'Beirne

Company Name: Unimed Pharmaceuticals, Inc.

Phone: 847-282-5449

Subject: Trade Name Decision

Date: January 26, 2001

Pages including this sheet: 1

From: Sandy Birdsong
Phone: 301-594-5334
Fax: 301-594-5494

Dear Mr. O'Beirne:

As per your request, this is to confirm information given to you by telephone on January 12, 2001. The Office of Post-Marketing Drug Risk Assessment has completed their proprietary name review and does not recommend the use of the proposed proprietary name, Teveter [redacted] but has no objections to the use of the alternate name, Teveten HCT. Additionally, this is to inform you that your proposed proprietary name must be re-evaluated by OPDRA approximately 60 days (and not more than 90 days) prior to the approval of the application.

Sincerely,
Sandy Birdsong, Regulatory Health Project Manager